EIF2A and neoplasm: Results showed that the combination treatment groups of both MDA-MB-231R and MCF-7R tumors showed the strongest expression of p-eIF2α, indicating the increased phosphorylation of eIF2α would indeed potentiate the therapeutic effect of PTX on MDA-MB-231R and MCF-7R tumor xenografts (Fig. 6G, H).